Kornimate/medical-research-clean huggingface dataset:
a pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine

Conditions: Schizophrenia; Auditory Hallucinations

Summary: the primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive transcranial magnetic stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the severity of auditory hallucinations. the secondary outcome is to evaluate the effects of the same rtms protocol on quality of life, functionality and general psychopathology.

seventeen patients with dsm-iv tr diagnosis of schizophrenia were randomized in two groups. first group received 20 sessions of 20 minutes each of low-frequency (1hz) rtms applied over the left temporoparietal cortex (ltpc). second group received sham (placebo) stimulation over the ltpc for the same period of time. all patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and refering auditory hallucinations occuring at least 5 times a day.

Eligibility criteria:
inclusion criteria: * patients with dsm iv tr diagnose of schizophrenia with treatment-resistant auditory hallucinations. * use of at least 400mg/day of clozapine * men and women from 18 to 65 years old * fertile women must be using adequate contraceptive method * bprs score of at least 27 exclusion criteria: * suicide risk * patients with epilepsy, brain surgery and/or head trauma in the past, use of cardiac pace maker or metalic clip in the head * diagnose of substance abuse/dependance * severe uncontrolled organic disease that may interfere in the patient´s participation in the study * any other reason that, in the investigator´s opinion, might interfere with the patient´s participation in the study, such as non compliance.

Keywords: refractory schizophrenia rtms auditory hallucinations
effect of supragingival irrigators containing chlorhexidine on oral health in blood dyscrasia

Conditions: Severe Neutropenia; Thrombocytopenia; Chemotherapy; Blood Dyscrasia Patients

Summary: in this study , effectiveness of supragingival irrigators containing chlorhexidine is compared with routine oral health measures in patients with blood dyscrasia whom can not use effective oral health measures(e.g brushing ) due to their systemic condition(e,g,neutropenia ,thrombocytopenia,..)

since some patients with hematologic malignancies cannot brush effectively and are at increased risk of bleeding and infection due to severe neutropenia and thrombocytopenia we want to access whether a none invasive method ( water jet systems containing chlorhexidine ) can help this patients to get better oral health indexes in comparison with routine oral health measures in these type of patients.

Eligibility criteria:
inclusion criteria: patients with a blood dyscrasia, severe neutropenia and thrombocytopenia, absence of periodontitis, absence of any oral mucosal lesion in onset of study, patient consent exclusion criteria: diabetes mellitus, observation of any side effect (resulted from the device), severe oral mucositis in intervention group(grade 3 and4 who), edentulousness, intolerance of device in severely malaise patients, patient death

Keywords: oral irrigator leukemia blood dyscrasia oral health index simplified (ohi-s) supra gingival irrigator
collecting and storing tissue samples from women with or without breast cancer

Conditions: Breast Cancer

Summary: rationale: collecting and storing samples of tissue, blood, and urine from patients with or without breast cancer to study in the laboratory may help the study of cancer. purpose: this research study is collecting and storing tissue samples from women with or without breast cancer.

objectives: * to create a database that includes environmental, demographic, phenotypic, clinical, pathologic, genetic, and prognostic factors in large cohorts of women with different stages of breast cancer. * to create a tissue repository that contains dna, rna, or protein from tumor tissue or normal tissue, peripheral blood lymphocytes, and plasma that are linked to frozen and/or paraffin-embedded pathology specimens. outline: patients undergo tumor tissue and normal tissue sample collection at the time of medically indicated surgery or biopsy. archival tissue may also be collected. patients and normal volunteers also undergo blood and urine sample collection. a repository of tissue, blood, and urine samples will be established to facilitate current and future research studies to learn about the biologic features of breast cancer development and progression. research studies may include molecular pathology studies and gene and protein expression studies. patients' medical records are reviewed over approximately 5 years to determine if the test results are associated with health status. patients do not receive the results of individual testing.

Eligibility criteria:
* breast lesion which is suspected to be cancer or a known diagnosis of breast cancer (any stage, at any point in the disease trajectory) who agrees to donate tissue/body fluids. * individuals of all races and ethnic groups are eligible for this trial. there is no restriction regarding age, race, or ethnicity. the trial is open to the accrual of men and women. * must sign informed consent for study of tumor specimens as part of a research project. * must give permission for their tumor specimens to be obtained from outside institutions for molecular analyses. * must be willing to be followed for recurrence, relapse and death from disease. eligibility criteria for optional physical function and cognitive assessments * must be 60 years of age or older * have completed initial round of cancer treatment * have completed the optional online survey and opted-in for the physical function and cognitive assessments

Keywords: breast cancer stage ia breast cancer stage ib breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer
efficacy trial on meningococcal b vaccine for preventing gonorrhea infections

Conditions: Gonorrhea; Sexually Transmitted Infection

Summary: objectives: efficacy of a meningococcal vaccine against neisseria gonorrhoea (ng) infection among men who have sex with men (msm). design: parallel randomised double-blind placebo-controlled trial. setting: a teaching hospital in hong kong. participants: 150 adult msm at risk of gonorrhoea infection (condomless sex with more than one man within the last six months, history of sexually transmitted infection \[sti\] diagnosis, inclination to have condomless sex, and other prep-eligible criteria) would be recruited into the trial, with half allocated to intervention and control group each. intervention: intervention and control group would receive, one month apart, two doses of meningococcal vaccine and normal saline, respectively. main outcome measures: safety and efficacy of vaccine against gonorrhoea (time to first gonorrhoea infection and incidence), and behavioural change after vaccination. expected results: ng incidences in two groups would be compared. efficacy of vaccine against gonorrhoea would be determined after controlling confounding variables. characteristics of participants with incident ng would be distinguished from those without incident infections. change of frequency of sexual activities and networking would be noted. implications: strategies on sti screening and vaccination could be informed. reduced sti burden post-vaccination could be measured with surveillance system.


Eligibility criteria:
inclusion criteria: * male adult who has had sex with another male in the past six months * ages 18 years or above * normally resides in hong kong * able to communicate in written and spoken chinese or english * at risk of gonorrhoea infection (had condomless sex with more than one man within the last six months, history of sti diagnosis, inclination to have condomless sex, and other prep-eligible criteria) * negative ng test result at the time of recruitment * no history of previous vaccination with menb vaccines * able and willing to attend all study visits exclusion criteria: * contraindications to receive menb vaccine * unable to give informed consent
a study of a new medicine (gw597599b) for the treatment of major depressive disorder

Conditions: Depressive Disorder, Major

Summary: a placebo controlled study evaluating efficacy and safety of medication in patients with major depressive disorder (mdd)


Eligibility criteria:
inclusion criteria: * patients meet the diagnosis of major depressive disorder (mdd). exclusion criteria: * patients with a primary diagnosis other than mdd. * patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder. * patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit. * patient is actively suicidal. * patients who have a history of migraine headaches.

Keywords: depression psychiatry major depressive disorder
quality control of a strengthening protocol in subjects with spinal cord injury

Conditions: Spinal Cord Injury, Acute

Summary: the aim of the master's thesis is to evaluate the clinic-internal strengthening concept of the swiss paraplegic centre (spz). the spz is a rehabilitation clinic for spinal cord injured people. the strengthening concept has been routinely used since 2015. by default, the patients complete - depending on which training phase they are in - three to four strength training sessions per week. as part of the master's thesis, the development of maximum strength of patients with spinal cord injury (sci) in primary rehabilitation will be studied. it is explicitly taken care of that the patients comply with the training requirements. furthermore, factors which prevent a consistent buildup of strength - such as medical complications (pressure sores, pneumonia, urinary tract infections) - are systematically recorded. the findings should provide information on the effect and qualitative transfer of the existing strength concept in everyday clinical practice. the strength training performed is accompanied by the master student and documented in a standardized manner.


Eligibility criteria:
inclusion criteria: * patients in initial rehabilitation * sci level c1-c5 (asia score c-d) * sci lever c6-l5 (asia score a-d) * traumatic and non-traumatic sci * disease-related paraplegia, high-grade stenoses and central cord syndromes * age \>= 18 years * the maximum force is tested on three predefined training devices, two devices for the upper and a device for the lower extremity. the participants will only be included in the study if they are capable of succeeding in at least both exercises for the upper extremity exclusion criteria: * polyneuropathic diseases such as critical illness and guillain barré syndrome * degenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis etc. * cognitive impairments * compliance of less than 2/3 of the training sessions * ≥ 14 days without training * more than 6 weeks between assessments

Keywords: exercise rehabilitation
effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization in patients with hepatocellular carcinomas

Conditions: Carcinoma, Hepatocellular

Summary: micronecrosis is a novel pathological feature of hepatocellular carcinoma (hcc). this study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (tace) in patients with hepatocellular carcinomas, and further exploring the value of micronecrosis for guiding tace in hcc management.


Eligibility criteria:
inclusion criteria: * (1) pathologically confirmed hcc (2) achievement of r0 resection. exclusion criteria: * (1) simultaneous presence of other tumors ; (2) receipt of preoperative anti-tumoral treatments; (3) concurrent treatment with other antitumoral therapies in combination with tace; (4) tumor necrosis that could be observed by gross examination; (5) a lack of necessary preoperative laboratory test results.

Keywords: hepatocellular carcinoma tace tumor necrosis
unid rods register

Conditions: Idiopathic Scoliosis; Spinal Curvatures; Spondylolisthesis; Degenerative Scoliosis

Summary: retro-prospective study allowing inclusion of patients with spinal deformities treated by patient-specific rods (unid). this study aims to assess performance, clinical outcomes and safety

despite decades of treatment and great diversity of instrumentation, the objective of sagittal spinal realignment in adult spinal deformity is achieved in only 38% of patients which reflects an inadequacy of the approach currently used. patient specific rods were created by medicrea to address this gap and support surgeons in achieving what they planned to perform in terms of spinal correction based on preoperative x-rays analyses. beside to help surgeons in planning and to improve performance, the avoidance of manual bending is supposed to save time during surgery and to limit notches which should then reduce rod fractures responsible for surgical revisions. a european register-like study has been set-up to assess radiological performance, clinical outcomes and revision rate following implantation of patient-specific rods in adult spinal deformities

Eligibility criteria:
inclusion criteria: * patient operated with unid® patient specific rods from medicrea® international * patient affiliated to health care insurance (social security in france) * patient able to complete a self-administered questionnaire * patient able to sign a disclosure form or a non-opposition form exclusion criteria: * patient not operated with patient specific rods from medicrea® international * pregnant patient * patient not affiliated to health care insurance (social security in france) * patient unable to sign a disclosure form * patient unable to complete a self-administered questionnaire

Keywords: sagittal alignment surgical planning patient-specific adult spinal deformity
different doses of colchicine on hscrp

Conditions: Coronary Artery Disease; Percutaneous Coronary Intervention

Summary: colchicine reduced atherothrombotic cardiovascular events in the colcot and lodoco2 studies. us food and drug administration approved colchicine as the first anti-inflammatory drug for cardiovascular diseases on june, 2023. however, there is a lack of evidence for colchicine in east asian population with coronary heart disease, and its effectiveness and safety need further exploration. therefore, this study aims to use different doses of colchicine to treat patients with coronary heart disease after percutaneous coronary intervention, explore the effects of different doses of colchicine on hscrp levels, and find the optimal dose of colchicine for treating coronary heart disease in china.


Eligibility criteria:
inclusion criteria: 1. volunteer to participate, understand and sign an informed consent form; 2. age ≥ 18 years old, regardless of gender; 3. patient diagnosed with coronary heart disease requiring percutaneous coronary intervention; 4. complete all planned percutaneous coronary intervention during hospitalization; 5. patient must be treated according to national guidelines for standard treatment of coronary heart disease. exclusion criteria: 1. known allergies to colchicine; 2. colchicine was taken within 10 days before randomization; 3. abnormal liver function test (alanine aminotransferase \>3 times the upper limit of normal value); 4. abnormal renal function test (egfr\<30ml/min); 5. thrombocytopenia (platelet count \<100 g/l); 6. uncontrolled infectious diseases; 7. known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, and malignant tumor, etc; 8. pre-existing or plan for the administration of nonsteroidal anti-inflammatory drugs, hormones, immunomodulatory drugs, or chemotherapeutic drugs; 9. pregnant women, lactating women or women of childbearing age who do not use effective contraceptives; 10. any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
londrina activities of daily living protocol in idiopathic pulmonary fibrosis patients

Conditions: Idiopathic Pulmonary Fibrosis; Activity, Motor

Summary: the londrina activities of daily living protocol was first developed for chronic obstructive pulmonary disease patients and was found to be valid and reliable, but there is no validity and reliability study of the londrina activities of daily living protocol in ipf patients. the purpose of the study is to examine the validity and reliability of the londrina activities of daily living protocol in idiopathic pulmonary fibrosis (ipf) patients.

idiopathic pulmonary fibrosis (ipf) is an interstitial lung disease characterized by a restrictive type of breathing disorder. in ipf patients, serious limitations occur in the activities of daily living (adl) of the patients due to dyspnea and fatigue symptoms, therefore it is very important to evaluate the activities of daily living in this patient group. it is recommended to use protocols created from activities frequently used in daily life to evaluate adl in chronic respiratory patients. londrina activities of daily living protocol is a performance-based objective measurement method based on repetition of daily activities. participants are asked to perform the activities defined in the protocol at the same speed they do at home, and the completion time of the protocol is recorded. the individual is asked to complete all stations in order from a designated starting line. the londrina activities of daily living protocol was first developed for chronic obstructive pulmonary disease patients and was found to be valid and reliable, but there is no validity and reliability study of the londrina activities of daily living protocol in ipf patients. the purpose of our study is to examine the validity and reliability of the londrina activities of daily living protocol in ipf patients.

Eligibility criteria:
inclusion criteria: 1. being diagnosed with idiopathic pulmonary fibrosis (ipf) disease 2. being 18 years or older 3. being independent in daily living activities 4. being able to read and understand turkish exclusion criteria: 1. the patient refuses to participate in the study 2. people with comorbidities that would make it impossible to perform any of the study evaluations (orthopedic pathology, uncontrolled cardiovascular or neurological conditions, psychiatric illness, etc.) 3. presence of infection in the last 3 months 4. those who show changes in their usual symptoms during the protocol 5. patients who have difficulty understanding the commands given 6. those who cannot complete all evaluations

Keywords: idiopathic pulmonary fibrosis activity daily living validity reliability
colon capsule endoscopy versus standard colonoscopy in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the dimension of diagnostic procedures and therapy of chronic inflammatory bowel diseases largely depends on the degree of mucosal inflammation. video colonoscopy is currently the gold standard in the evaluation of the mucosa in patients with ulcerative colitis (uc). pillcam colon capsule was developed by given imaging, israel, as possible alternative imaging modality to evaluate mucosal changes in patients with uc. the colonic mucosa can be visualized and recorded by video while the colon capsule passes the colon. many patients suffering from uc ask their physician for possible alternative diagnostic imaging because they are uncomfortable with conventional colonoscopy. the primary aim of the present study is to compare the new pillcam colon capsule with standard colonoscopy with respect to assessing mucosal disease activity and localization of inflamed colonic mucosa in patients with known uc.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age with * known ulcerative colitis * indication for standard colonoscopy * informed consent given by the patient exclusion criteria: * patient has dysphagia * patient has congestive heart failure * patient has renal insufficiency * patient is known or is suspected to suffer from intestinal obstruction * patient has a cardiac pacemaker or other implanted electronical medical devices * patient is pregnant * patient has had prior abdominal surgery of the gi tract * patient has any condition, which precludes compliance with study and/or device instructions. * age less than 18
skeletal muscle parameters of liver cirrhosis in non-invasive imaging and outcome

Conditions: Liver Cirrhosis

Summary: the principal aim of this study is to analyse l3-smi (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and tips (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with tpmt (transverse psoas muscle thickness). furthermore, the role of myosteatosis, determined in ct by l3-smi, mri and ultrasound will be studied.

the principal aim of this study is to analyse l3-smi (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and tips (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with tpmt (transverse psoas muscle thickness). furthermore, the role of myosteatosis, determined in ct by l3-smi, mri and ultrasound will be studied.

Eligibility criteria:
inclusion criteria: * liver cirrhosis of any etiology * ct scan available exclusion criteria: * hcc or any malignant disease

Keywords: sarcopenia cirrhosis transjugular intrahepatic portosystemic shunt tips acute-on-chronic liver failure aclf
non-comparative study of treatment with induction chemotherapy with cisplatin and gemcitabine followed by chemoradiation or definitive chemoradiation in invasive locally advanced carcinomas of uterine cervix.

Conditions: Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t

Summary: the purpose of this phase ii study is to determine the survival free disease of patients diagnosed with invasive locally advanced carcinomas of uterine cervix treated with induction chemotherapy with cisplatin and gemcitabine followed by chemoradiation and definitive chemoradiation.


Eligibility criteria:
inclusion criteria: 1. advanced carcinoma of uterine cervix histological confirmed. 2. indication for definitive chemoradiation treatment; 3. measurable disease by recist 1.1 (response evaluation criteria in solid tumors) criteria; 4. age between 18 years old and 70 years old; 5. adequate bone marrow and organ function defined by laboratory values; 6. non evidence of disease in para-aortic lymph node; exclusion criteria: 1. previous treatment with chemotherapy or radiotherapy 2. previous surgery for primary tumor; 3. distant metastasis; 4. performance status according to eastern cooperative oncology group greater than 2; 5. peripheric neuropathy greater than grade 2 by national cancer institute common toxicity criteria for adverse events (nci-ctcae) version 3.0; 6. significant cardiac disease (history of and/or active disease); 7. other treatment for cancer, including hormonotherapy; 8. psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements;

Keywords: advanced carcinomas of uterine cervix chemoradiation chemo-induction cisplatin gemcitabine